BE HOLDING and HOLD ON TIGHT.
$ABVX was a $5 Stock in the Days Leading up to its P3 Result it Doubled to $10 --- When the Result was Announced
- there was T1 TRADING HALT
- and GAP UP 600% to $60 In and Instant
-- and it Kept CLIMBING to a HIGH OF $148
... Something Very Similar is about to Happen Here - any day now.
$6 Stock is about to be a $60 Stock and Climbing.
Your Daily Reminder u/yG19 is actually paid to post here, and elsewhere by SHORT LONG Funds.
the EVIDENCE is in the Fact - It Cannot - Deny it.
u/yG19 is Unable to Post the words " I AM NOT PAID TO POST "\
It is LYING ABOUT THE TIMELINE.
NOW YOU KNOW --- Ps Ask it ... see what happens.
PSSS ASK IT - and SEE WHAT HAPPENS...
Don't @ me ... ASK IT.... u/commercial-ad9959
even its name is admitting it, is a commercial ad.
Look at the Chart - when the 60th and the 72nd was announced.
Its Time to be Holding a Full Bag.
… its now May.
Given the Variable nature of events and the extended length of Survival for these TRANSPLANT INELIGIBLE Patients who Harbor Significant CoMorbidities remaining in trial, - there could easily be a rapid spate of successive events, at any time, and Institutional Funds, and all interested/invested parties must reconcile their positions with the Fact, we could see Final Topline Results any day now.
https://www.reddit.com/r/sellasLifescience/s/4WGeMcpt3b
Gps Phase 3 Registrational Results are coming - Giving Gps the FDA GREEN LIGHT to treat 100,000 AML Patients Currently in Remission and 50,000+ New Patients each Year
- a massive $28B TAM
- worth $40B to Big Pharma $180 per share, only a matter of time
- they are inevitable - it is inevitable that SLS Shares Will Be Launching -- we Are Officially in the ANY DAY NOW Zone -- A.D.N. Defined.
\- Events are NOT Linear this far along in a OS trial for AML Cr2 Patients,
- As of TODAY \*:
**at Least 47 REGAL Phase 3 Patients Remain Alive At Least 26 Months, ranging up to 62 Months.**
\- We have Enrollment Completion March/April 126/7 Patients
All Along the Time Points on the OS Plot curve - some patients remain alive at Least, 26 months - Some maybe 30 Months, 40 Months or 50...
Ranging UP To ... means there will be a # Patients in Trial 3 years 4 years and 5 ... and a great many may now be in Hospice, or well may have been after the Holidays - ANY DAY NOW is Not a Long Time to Wait for a Possible 47X ROI . . .
\- Note: Dec 26th CRO cutoff of 72 Events Did NOT Include Events from the Prior weeks, due to the Holidays
\- and the normal lag, from an event, patients families will need to inform the Dr. / Clinicians - takes some number of days/weeks, as families are not in a hurry/not a priority, dr's then will need to update the CRo - another number of days etc.
to be clear - the Dec 26th 72nd event PR DID NOT Include any events from the Prior 3 or 4 weeks, and no Post Holiday, Christmas/ New Year Events.
\- sad as it is, patients often hang on through the holidays, and let go after and during the Winter Terminus - AML Event Rates are Documentedly Higher during the Winter Months.
Investors must reconcile the Fact we could See 80 Events any day now \\\* Phase 3 Results are Imminently Due.
Bottom Line:
\* there were more than 72 Events in Dec.
--- July vs NOV 2023 - enrollment Lag
**Recall SLS expected 3D MED adding 25 -40 patients in Q2/ Q3/ Q4 2023 - Litigation Commenced in Dec 2023 along with Enrollment.**
\-- AND the Enrollment Back Loaded, MD Anderson Ucla Geffen, Baylor Med, Mayo Clinic sites, among others Discontinued Enrollment Mid/ 2023 - in July all these Sites had Closed Enrollment per there own websites, Given SLS was at 90-95 End of Q3 and Everyone Expected 3D MED to add 25-40 patients.
3DMED Litigation Initiated DEC 2023 - at Which TIME Enrollment Resumed and Completed in March - 22 Patients Added at the VERY End - who are ALL NOW in Trial at Least 22 months / there will be a Spate of Events From this Group / outside the normal event rate boundary.
**- We Should Expect to See the Phase 3 Top Line Results ANY DAY NOW - and Smart Money is**, **has been and will continue Moving Into Position.**
\- its going to be sooner than later to see 80.
\- Given all we know about BAT - there are 60 events +/- from control - in trial AT LEAST 26/27 months
126/7 Enrolled
\- 30 months - 105 enrolled Nov 2023
\- “you will not see survival past 12” Dr. Jamy.
then another 12 ish Events from GPs non Responders
72 Events accounted for.
\- Long Institutional Money is Feasting on every short sold shore, whether it's actual Short or Short Term Penny Flip Shares. At a certain point, the 'float' will be gone and SLS share prices will be climbing the Stairway to Heaven.
\* they're not ... you can find the details in prior posts.

When - When is the $40B Question.
= ADN
SLS Market Cap is now up over 1,000% Since the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM ANALYSIS at 60 Events DEC 2024.
The unblinded data - Gave most HEME Industry Players a good sign Gps is Golden, now 6 months since the 72nd Event, and this far along - 25 months since enrollment completed, and median follow-up of 31 months (25-63) ALL Smart Investors must reconcile the fact the 80th event and instant share price launch could occur at any time.
Enrollment completed a solid 25 months ago - 13.5 months of Follow-Up at Interim, Now 31 months Follow-Up in a setting of "High Leukemic Risk" Dr. Kantarian Chair of MD Anderson's Leukemia Dept., REGAL Phase 3 Global Lead and Steering Committee Chair.
- AML CR2 Maintenance Transplant Ineligible Setting, where 3 Dr's treating actual patients are on record stating MOS for BAT is only 6-8 months, Aza/VEN BAT Failed 3 Recent P3 trials, including VIALE-M AML CR1 Remission Maintenance.
- Dr. Jamy - largest enrolling US clinicians, was asked what's the longest OS on BAT he sees in his practice. '6-8 Months MEDIAN', 'you will not see survival past 12 months', in any trial.
31 Month Median Follow up - Ranging to 63 months, Long Tail Survivors
are now exceeding OS for CR1 Transplant.
Every day - GPs Value Grows, as more investors / fund analysts, discover and become more convinced - It's Gps causing the Near Miraculous All Pooled Survival.
Unfortunately, we have to reconcile the Fact there could be a Rapid Spate of events and the 80th is announced.
*protip: Review SLS Share Price Since the Dec 2025 72 Event Announcement.
$SLS $PFE $LLY $ABBV Smarter than you, know this Enhanced Dosing Discovery by Harvard Professor, Dr. Amrein Completely deRisks 009.
Dr. Amrein's data Confirms 009 Future Data - will Be Better - than Prior P2B SLS009 data published at ASH,
- which was better than data that got bought for $4.9B.
$SLS $0.888B 600% ROI on the Table - FREE MONEY
SLS009 P2B ORR of 57% for End Stage AML-MR END STAGE Patients will be IMPROVED in Front Line with Enhanced Dosing. It is Certain.
